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1. Introduction
Pancreas Transplantation aims at providing Beta cells replacement in diabetic patients,
especially for type 1 diabetes recipients in whom Beta cells had been destroyed by an autoim‐
mune process. The final achievement is to restore a normal physiological control of glucose
metabolism in order to halt or reverse the secondary complications of diabetes i.e. retinopathy,
neuropathy, nephropathy, micro – and macro - angiopathy [1]. That can be achieved by a
vascularised pancreas graft (referred as Pancreas Transplantation, PT) or by islet grafting
(referred as Islet Transplantation, IT). The former PT includes transplanting 95% of unuseful
cells, the exocrine part from one pancreas, while the last one IP, embolizing into the recipient
liver, Islets of Langerhans after digestion and purification of several human pancreases. Three
types of PT can be performed: the pancreas and a kidney are simultaneously transplanted with
a single induction of immunosuppression (IS) therapy in hoping to correct both uremia and
diabetes mellitus (SPK = Simultaneous Pancreas and Kidney Transplantation); the pancreas is
transplanted after a successful kidney graft allowing two induction therapies along with the
basic IS treatment (PAK = Pancreas After Kidney Transplantation) ; and finally the Pancreas
can be transplanted alone in pre-uremic recipients with unawareness hypoglycaemic events
or with rapidly evolving secondary complications of diabetes such as proliferative retinopathy,
or advanced neuropathy (PTA = Pancreas Transplantation Alone) [1].
Moreover, in SPK, both organs the Pancreas and the Kidney are procured from the same
deceased donor, either donor after brain death (DBD) or donor after cardiac death (DCD). In
some US institutions, a segmental pancreas and the left kidney, are procured in a living donor
[2], using a laparoscopic approach in the more recent year [3]. For PAK, in order to avoid an
excessive IS load and two induction therapies, other institutions had proposed whenever
possible to keep in stand-by the potential live kidney donor until a cadaver whole pancreatic
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compatible graft is available [1]. By contrast, the number of PTA remains limited in non uremic
recipients with life-threatening complications of diabetes, in whom one might hope to avoid
the hypoglycaemic events with a successful graft. That can also be achieved with IT. But except
for rare cases, insulin independence with IT requires more than a single human pancreas and
is limited over time [1]. Moreover, IT needs costly materials, chambers and rooms for prepa‐
ration. That’s why IT will not be included in the present report.
2. The history of surgical techniques in pancreas transplantation
The first pancreas transplantation performed by W. Kelly and R. Lillehei on December 17, 1966
at the University of Minnesota was a duct ligated segmental graft which was implanted in the
left iliac fossa along with a kidney coming from the same cadaver donor in a 28 year old female
uremic recipient with type 1 diabetic nephropathy [4]. It was the first ever SPK (Fig 1). The
recipient was insulin-free for six days; later she needed exogenous insulin, the need being
attributed to the high doses of steroids given to prevent rejection. However, she also developed
graft pancreatitis, that was most likely related to duct ligation, and for which she received 950
Rads graft irradiation. On February 14, 1967, Kelly and Lillehei removed the pancreas and
rejected kidney. The recipient died from pulmonary embolism 13 days after pancreas graft
removal [4]. This first case exemplified many of the problems that were associated with TP
over the following 2 decades: surgical complications, wound infections, and graft rejection.
Figure 1. Drawing of the first segmental pancreas transplant (from Kelly et al.) [4].
Lillehei was the lead surgeon in the second pancreas transplant, also done with a kidney (Fig
2). He went on to do a total of 13 cases between the first case of Kelly and 1973, 9 with a kidney
and 4 without [5, 6]. Significant changes in surgical techniques were made between the first
and the second transplant pertaining to graft size (whole organ versus segmental) and duct
management (cutaneous duodenostomy versus duct ligation). Lillehei transplanted the
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donor’s whole pancreas and attached duodenum extraperitoneally to the 32-Year-old recipi‐
ent’s left iliac fossa (Fig 2). This transplant achieved a more prolonged state of graft function,
but rejection treatment had to be instituted three and eight weeks post-transplant. Both
rejection episodes affected the graft duodenum. The recipient was on insulin when she died
four months post transplant from sepsis.
Figure 2. Drawing of the first whole pancreas transplant with cutaneous graft duodenostomy (from Lillelei et al.) [5]
After that series of 13 Pancreas Transplants, R. Lillehei concluded that most complications were
associated with kidney graft rejection without pancreas rejection and recipient death [5, 6, 7].
After the first four pancreas transplants at the University of Minnesota, the next four trans‐
plants were performed in South America in 1968; [8, 9, 10]; three were performed in Brazil and
one in Argentina at the Buenos Aires Hospital. Only one functioned sufficiently to induce
insulin-independence and was subsequently lost to rejection at 4 months. [10].
In 1969, two other U.S. institutions performed one SPK transplant each: one at the University
of Colorado (Fred Merkel and Thomas Starzl) and one at the University of California, Irvine
Medical Center (John Connolly). [8, 11]. The first pancreas transplant in Europe, along with a
kidney transplant, was performed in 1972 at Guys Hospital, in London, U.K. (Mick Bewick). [8].
By the 1970s, only 25 pancreas transplants had been performed at six institutions worldwide.
Two-thirds of those early pancreas transplants were done along with a simultaneous kidney
transplant. Exocrine secretions had been drained by duct ligation, cutaneous duodenostomy,
or enteric drainage using a Roux-en-Y loop. Of these 25 grafts, only one, from Lillehei’s original
series, functioned for almost one year, and none for more than one year.
On November 24, 1971, Marvin Gliedman at Montefiore Hospital and Medical Center in New
York performed the first pancreas transplant using urinary drainage via the native ureter [12].
Gliedman and associates performed a total of 11 ureteral pancreas transplants in the early
1970s (Fig 3) with one graft functioning for 22 months and another for 50 months – at that point
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the longest pancreas graft survival recorded. [13, 14]. However, ureteral drainage did not find
widespread application because of tenuous leakage-prone duct-to-ureter anastomosis; leakage
from the pancreas cut surface; and the potential need for ipsilateral native nephrectomy. The
main conclusion drawn from that original and historical series was the probable evidence of
a hierarchy in rejection, the pancreas being less antigenic than the kidney the latter being less
antigenic than the duodenum [15]. Therefore, surgical techniques using a segmental pancreatic
graft (body and tail) were developed during the next decade.
Figure 3. Ureteral pancreas transplant according to Gliedman et al [12] end-to-end distal ureter to pancreatic duct
anastomosis.
2.1. The segmental pancreas transplantation reign (from mid 70’s to mid’s 80’s)
In the mid 70’s, the segmental pancreas while avoiding the duodenal segment was the most
popular technique used for PT [6, 7]. Various procedures were proposed to drain the exocrine
secretion: the duct could be left opened with the segmental graft placed intraperitoneally (Fig
4) [16] or blocked by an intraductal injection (Fig 5) of either Neoprene (J.M. Dubernard) [17] or
Prolamine (W. Land) [18] or Polyisoprene (P. Mc Master) [19] or Silicone (D.E.R. Sutherland) [20].
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Figure 4. Technique for revascularization in the recipient of a segmental pancreas graft. The celiac axis (on a Carrel
patch) and portal vein of the graft are anastomosed to the commun iliac vessels of the recipient through the meso-
sigmoid [16].
Figure 5. Injection of a synthetic polymer into the duct of a segmental pancreas graft following revascularization. Ap‐
proximately 4-6 ml of the polymer is injected, followed by ligation of the duct [17-20].
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Twelve intraperitoneal open-duct segmental pancreas transplants were performed at the
University of Minnesota in a two-year period [16]; four were rejected within 4 months; 3 had
to be removed because of peritonitis or ascites. The latter recipient lived insulin-independent
for 18 years until in 1996 she died from a trauma, with a functioning graft, the longest duration
of function at that time [21].
By contrast the duct occlusion technique became more popular despite numerous leaks,
pancreatic fistulae, graft pancreatitis and vascular thrombosis. For managing these complica‐
tions, Dubernard et al. [17, 7] proposed the omentoplasty in warping the duct-occluted
segmental pancreas with the omentum, while Calne et al. [6, 7] was performing an A-V fistula
at the distal end of the pancreas tail (Fig 6; panels A and B).
 
(a) (b) 
Figure 6. Panel (a): omentoplasty according to Dubernard et al.[7, 17]. Panel (b): AV fistula between the distal splenic
artery and vein according to Calne et al. [6, 7].
During the late 70’S, three major events occurred that contributed to the development of
PT.
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Firstly, in 1979, the clinical use of Cyclosporine A (CsA) by R. Calne et al. [22] as the single
immunosuppressant in 36 recipients of cadaveric organs. CsA remained the basic immuno‐
suppressive (IS) drug up to the early 90’S.
Secondly, in 1980, the organization by J.M. Dubernard in Lyon, France, of the first pancreas
transplantation  meeting,  launching  the  International  Pancreas  (and  Islet)  Transplant
Registry (IPTR) which was handled by D.E.R.  Sutherland at  the University of  Minneso‐
ta [23].
Thirdly and finally, in 1981, the first of a series of 5 workshops – called the Spitzingsee Meeting
– organized by W. Land in Kühtai, Austria [24]. The characteristics of these workshops
consisted in gathering the world pioneers in PT and allowing them to discuss on not only the
successes but also the failures, finding ways to prevent them or improve the results [25]. These
meetings were also the basis of creating the International Pancreas and Islet Association
(IPITA) and later on, in Europ, the European Study Group in Simultaneous Pancreas and
Kidney Transplantation (EuroSPK) [25]. More recently, was created the EPITA, the European
Pancreas and Islet Transplantation Association [25].
During one of these workshops, H. Sollinger [26] had the idea to renew an old technique
and divert the exocrine secretion of the pancreas into the bladder (Fig 7), while G. Tyden
[27] and C. Groth [28] were proposing the enteric drainage (Fig 8).  Slowly, both groups
moved from the segmental graft [28] to the whole pancreas graft along with a duodenal
segment (Fig 9) [26, 27].  This announced the end of the segmental transplantation reign.
In  the  mean  time,  on  November  10,  1982,  the  first  pancreas  transplantation  was  per‐
formed in Belgium by J.P. Squifflet and G.P.J. Alexandre [7]. The recipient was a 29 year
old female with a 26 year history of type 1 diabetes. She was on peritoneal dialysis since
one  year  and  switched  to  hemodialysis  a  month  before.  She  received  a  simultaneous
pancreas and kidney transplants from a 22 year old female cadaver donor who died in a
car accident from a head trauma. The recipient did not share any HLA antigen with the
donor.  She received a segmental  pancreas graft,  anastomosed on a Roux-en-Y loop (Fig
10), according to the technique described by Groth et al. (Fig 8) [23]. The immunosuppres‐
sive therapy consisted in a short course of antilymphocytic globulins induction along with
cyclosporine A and steroids. She was one of the first few patients who received cyclospor‐
ine A in Belgium, at a dose a 14 mgr/kg/day. Following an episode of delayed graft function
of the kidney, she fully recovered and was insulin free for a period of 2 years. Than insulin
resistance was noticed along with an increase of 15 kg in body weight. Despite Cyclospor‐
in and steroids dose reduction and the introduction of azathioprine, insulin therapy was
resumed. She eventually went back on hemodialysis 8 years later and died in June 1992
while waiting for a second kidney transplant. The choice of the surgical technique and IS
was  based on animal  experiments  [29–32]  but  also  on  the  fact  that  segmental  pancreas
transplantation was more popular during that period.
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Figure 7. Exocrine secretion of segmental grafts drained directly into the bladder, as first described by Sollinger et al. [26].
Figure 8. Enteric drainage of a segmental pancreas graft to a Roux-en-Y limb of recipient jejunum. The temporary
external drainage of the pancreatic duct secretions to the catheter brought to the Roux-en-Y loop and the abdominal
wall is illustrated [28].
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2.2. The whole pancreas transplantation reign (from mid 80’s)
Thus, in the mid 80’s, whole pancreas transplantation with a duodenal segment became the
gold standard surgical procedure.
In 1987, Nghiem and Corry at the University of Iowa described the technique of bladder
drainage via a graft-to-recipient duodeno-cystostomy for whole pancreaticoduodenal grafts
(Fig 9) [33]. Most U.S. and European centers quickly adopted bladder drainage via the graft
duodenum. For SPK transplants, the dominant reason to use bladder-drainage was to reduce
the risk of anastamotic leaks, since rejection could be monitored by serum creatinine. For
solitary pancreas transplants, bladder-drainage had the advantage of urine amylase monitor‐
ing for rejection.
Figure 9. Pancreaticoduodenal transplantation with bladder drainage. A side-to-side anastomosis of the duodenal
segment is made to the dome of the bladder [33].
In the mid 80’s, Starzl [34] and associates reintroduced in U.S.the technique of enteric-drained
whole-organ pancreaticoduodenal transplants, as originally described by Lillehei while the
Stockholm group continued to do enteric drainage by direct duodeno-enterostomy [35]. Nearly
everyone was convinced that whole pancreaticoduodenal transplants were preferable for PT
from cadaver donors, and after en – bloc liver and pancreas procurement (Fig 11), transplant
surgeons designed methods for reconstructing the vasculature to both organs (Fig 12) [36 - 39].
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 (a) (b) 
) 
(c) (d) 
a: drawing of the procedure.
b: the segmental pancreas graft.
c: the end-to-end pancreas graft anastomosis to the Roux-en-Y loop.
d: the anastomosis suture was protected by a catheter inserted into the pancreas duct.
Figure 10. Segmental pancreatic transplant in the first Belgian recipient with enteric diversion of the exocrine secre‐
tion, in a Roux-en-Y loop.
From the mid-80s to the mid-90s, bladder drainage became the most common technique
worldwide (Fig 9). However, because of chronic complications of bladder drainage (urinary
tract infections, cystitis, urethritis (Fig 13), reflux pancreatitis, hematuria, metabolic acidosis
and dehydration from fluid and bicarbonate losses), leading to conversion to enteric drainage
in approximately a quarter of the recipients, in the mid-1990s, surgeons began to shifted to
primary enteric drainage (Fig 14), not only for SPK transplants, but at some institutions also
for solitary pancreas transplants [40].
Current Issues and Future Direction in Kidney Transplantation258
Figure 11. Maneuvers for en-bloc removal of a whole pancreas and a liver from a cadaver donor with normal vascular
anatomy.The gastroduodenal artery must be divided so that the common and proper hepatic arteries can remain in
continuity and be retained with the liver. The portal vein is divided just superior to the entrance of the splenic vein.
Then, the pancreatic portion is lengthened by an iliac vein graft. The celiac and superior mesenteric arteries can re‐
main with the pancreas with a Carrel aortic patch. [38]
LHA = left hepatic artery.
GDA = gastroduodenal artery
SA = splenic artery
SMA = superior mesenteric artery.[39]
Figure 12. Whole-pancreas procurement and reconstruction of its arterial supply in a donor with a replaced / accesso‐
ry right hepatic artery (R / A RHA).
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 (a) 
(b) 
Figure 13. Chemical urethritis in a pancreas recipient with bladder drainage of the exocrine secretion (Panel (a)). CT
scan: same recipient (Panel (b)).
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Figure 14. Pancreaticoduodenal transplantation with enteric drainage. A side-to-side anastomosis of the duodenal
segment is made to the distal ileon, or the proximal jejeunum. It can also be performed on a Roux-en-Y loop [35].
2.3. The modern era of surgical techniques
Either enteric or bladder drainage is now done for virtually all pancreas transplants using a
whole pancreas graft with a duodenal segment. The other techniques are virtually never used
unless for salvage of a technical situation (e.g., duct injection might be used to manage a leak).
With regard to the venous drainage of pancreas grafts, portal would be the most physiological
but the systemic venous system was only accessed during the first two decades. Later on, the
use of portal drainage at the junction of the recipient’s superior mesenteric and splenic vein
was favored in recipients of enteric drained whole-organ pancreaticoduodenal transplants
(Fig 15). Surgeons reported on its metabolic and possible immunologic advantage, features
also noted at the University of Maryland, where a large program existed of conversion to
almost exclusive portal drainage [41]. By the end of the 1990’s, almost 20 % of pancreas
transplants in U.S. and in Europe were being done with portal drainage but the proportion
did not increase nearly as much as the proportion of pancreas grafts that were enteric drained,
reaching over 80 % for solitary in U.S. and over 90 % for SPK transplants in Europe (Fig 16).
Early diagnosis of pancreas rejection had been difficult from the beginning, in particular for
solitary pancreas transplants where serum creatinine could not be used as a surrogate marker
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like in SPK. That’s why there is still room for improvement in surgical techniques. In order to
have easy access to the graft for performing biopsies, De Roover et al. [42] proposed recently
a technical modification and a side-to-side duodeno-duodenal (D-D) anastomosis while using
a whole pancreaticoduodenal transplant with the venous effluent drained into the portal
system of the recipient (Fig 17, 18). It offers serial sampling of the duodenal transplant mucosa
by simple fibroscopies, a useful tool for monitoring rejection (Fig 18, Panel B). The duodenal
anastomosis can be hand-made or performed using a stapler device. But the major drawback
of both techniques could be the management of duodenal leaks on graft thrombosis. Our
experience in 11 pancreas recipients at the University of Liege, CHU Sart Tilman is summarized
in table 1. Peri-pancreatic collections, with or without pancreatitis were managed by surgical
exploration and drainage. So far, only one graft thrombosis (PTA) needed prompt removal but
was followed by a duodenal leak with cutaneous fistula which required weeks before healing
(table 1). Therefore, prospective studies will be useful to specify the place of the D-D and each
particular surgical suturing technique.
Figure 15. Pancreaticoduodenal transplantation with enteric drainage and portal drainage at the junction of the re‐
cipient’s superior mesenteric and splenic veins [41].
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Figure 16. International Pancreas Transplant Registry * Panel (a): US Pancreas Transplants per year, between
12/16/1966 and 12/31/2011. Panel (b): Duct management techniques (urinary versus enteric drainage) in US primary
pancreas transplants, between 1/1/1988 and 12/31/2011. Panel (c): Portal Drainage in enteric drained (ED) trans‐
plants. US primary pancreas transplants, between 1/1/1988 and 12/31/2011.
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 Figure 17. Pancreaticoduodenal transplantation with portal drainage and side-to-side recipient duodenal drainage of
the exocrine secretion [23]: schematic representation and positioning.
 
(a) 
(b) 
Figure 18. Pancreaticoduodenal transplantation with portal drainage and side-to-side recipient duodenal drainage of
the exocrine secretion [23]: Panel (a): per operative view Panel (b): endoscopic view of the duodenum
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Figure 19. International Pancreas Transplant Registry* Panel (a): Purcentage of 5 or 6 HLA A, B, Dr Mismatching in US
primary pancreas transplants between 1/1/1988 and 12/31/2011. Panel (b): Anti-T-Cell induction in US primary pan‐
creas transplants between 1/1/1988 and 12/31/2011. Panel (c): Major immunosuppressive protocols in US primary
pancreas transplants between 1/1/2007 and 12/31/2011
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 PTA hand-made (n=7): 
 Peri-pancreas hematoma + 
inflammatory syndrome (1)* 
 Graft thrombosis (1)*
 Pancreatitis + peri-pancreas 
fluid collection due to partial 
necrosis of pancreas (1)*
 PTA stapler (n=0)
 SPK hand-made (n=1): no.
 SPK stapler (n=3)
 Peri-pancreas fluid 
collection + inflammatory 
syndrome (1)*
 Digestive hemorrhage due 
to ulcers of the donor 
duodenal stump (1)
 Surgical exploration + 
drainage 
 Transplantectomy 
 Surgical exploration + 
drainage 
 Surgical exploration + 
drainage 
 Conservative 
treatment+transfusion 
Table 1. Complications and outcome in 11 recipients of whole pancreas grafts with duodeno-duodenostomy, at the
University of Liege, CHU Sart Tilman. The D-D anastomosis was hand-made (n=7) or using a stapler device (n=4)
3. The history of immunosuppression in pancreas transplantation
Advances in immunosuppressive protocols and the introduction of new immunosuppres‐
sants have had a major impact on and improved outcome after PT. As already mentioned,
in 1979, Calne and associates first reported the successful use of cyclosporine in two pancreas
recipients [22]. Due to the large dose of CsA used as a single agent and its nephrotoxicity,
Starzl et al. proposed to combined reduced doses of CsA with steroids [43]. Further decreased
in CsA dosages by using the synergistic effect of combining CsA to Aza was proposed by
Squifflet et al. based on animals experiments [29, 44]. Triple drugs combining CsA, Aza and
Steroids and later on quadruple drugs regimen with a short course induction of polyclonal
Antibodies was the mainstay IS regimen during the next decade [21]. Starzl and his team
first  reported  the  use  of  Tacrolimus  (Tac)  in  pancreas  allograft  recipients  during  the
investigative period in 1989. [45] After approval, the first report on the use of Tac for pancreas
transplantation  was  by  D.  Shaffer  and  associates,  successfully  reversing  ongoing  acute
rejection in two SPK recipients. [46].
A major topic of the 4th Spitzingsee Workshop (January 30 – February 02, 1997; Kühtai, Austria)
was the IS therapy in PT [25]. At that time, the newly introduced agent mycophenolate mofetil
(MMF) was proved to be superior to azathioprine (Aza) for the prevention of acute rejection
in kidney transplantation patients [47]. Data comparing Tac with the old (oil-based) formula‐
tion of CsA were also available in kidney transplantation, but there were some concerns about
Tac having a diabetogenic effect [48], specially for pancreas. A preliminary study investigating
the use of Tac in pancreatic transplantation, which was published by Gruessner et al., showed
that pancreatic graft survival at 6 months post transplant was higher with Tac (79%) than in a
historical group of SPK recipients treated with the oil-based formulation of CsA (65%; p = 0.04)
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[49]. During the same era, the new micro-emulsion (Me) formulation of CsA (CsA – Me) had
been introduced into clinical practice.
At that period, all European participants to the meeting were performing a limited number of
SPK per centre. All realized that local studies would not aim solving the IS problems. Therefore
W. Land took the opportunity to propose them the first large international prospective
multicentre study in the field of PT, comparing Tac to the new CsA – Me, along with MMF,
corticosteroids and a short course of induction therapy with Rabbit – antithymocyte globulines
(R-ATG, Fresenius, Germany).
The rationale for induction therapy using anti-T-cell agents was triple: minimizing the risks
of early rejection episodes, accelerating recovery of renal and pancreatic allograft function
(protection against the ischemic reperfusion injury) and perhaps, inducing a tolerogenic effect
to donor alloantigens. Before 1994, choices of maintenance IS agents were limited to a “one
size fits all” approach with the combined use of Cyclosporin A (CsA), azathioprine (Aza) and
corticosteroids. But, with that regimen, rejection rates were about 75 % to 80 %, with a rate of
25 % to 30 % of recurrence. Therefore, during the early 90’s anti-T-cell induction was auto‐
matically added in all 3 categories of pancreas transplantation (Fig 19, Panel B). The choice of
the anti-T-Cell agent was based more on its accessibility than on any rationale or scientific
approach; the anti-T-Cell agents which were used are: MALG®, OKT3®, ATGAM®, R-ATG®,
Simulect®, Zenapax®, Thymoglobulin®, Campath®. During the CsA era, single centre studies
emphasized the benefit of Quadruple over Triple therapies [50, 51]. Other comparative studies
underlined the best efficacy of ATG over OKT3® and MALG® [52 - 54]. During the modern
era, during which most centres were using Tacrolimus (Tac), Mycophenolate Mofetil (MMF)
and corticosteroids for maintenance therapy, Kaufman et al. designed several multicenter
studies [55, 56] in which they confirmed the usefulness of induction therapy in PT. By contrast,
the place of Campath®, still remains to be confirmed [57].
The results of the first Euro-SPK study were encouraging [58]. The 1-year incidence of biopsy-
proven acute rejection of the kidney or pancreas was lower with Tac (27.2 %) than with CsA-
Me (38.2 %; p = 0.09). Pancreatic graft survival at 1 year was significantly higher with Tac
(91.3 %) than with CsA-Me (74.5 %; p = 0.0014). Kidney graft survival was similar in the two
groups [58].
At 3 years, fewer patients receiving Tac (36.9 %) than CsA-Me (57.8 %) were discontinued from
treatment (p = 0.003). The initial episodes of biopsy proven rejection were moderate or severe
in just one out of 31 (3 %) Tac-treated patients compared with 11 of 39 (28 %) patients receiving
CsA-Me (p = 0.009).
While 3-year patient and kidney survival rates were similar in the two treatment groups,
pancreas survival was superior with Tac (89.2 vs 72.4 %; p = 0.002). Thrombosis resulted in
pancreas graft loss in 10 patients receiving CsA-Me and in only 2 treated with Tac (p = 0.02).
The overall incidence of adverse events was similar in both groups, but MMF intolerance was
more frequent with Tac whereas hyperlipidaemia was more frequent with CsA-Me. Acute
rejection was more common among CMV-infected patients (66 vs 41 % without infection; p =
0.001) and in those not receiving ganciclovir prophylaxis [48, 58].
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There were no differences in 3-year kidney pancreas or patient survival between the 0-3 and
4-6 HLA antigen mismatch (MM) groups. Significantly more patients with 0-3 MM (66 %) were
rejection-free at 3 years compared to those with 4-6 MM (41 %; p = 0.003). The relative risk of
acute rejection was 2.6 times higher among patients with 4-6 MM than among those with 0-3
MM [48].
In summary the Euro-SPK study findings provided evidence to support the use of Tac in
patients undergoing SPK transplantation.
A second SPK study addressed the issue of the choice of the antiproliferative agent which could
be associated to Tac, either MMF or rapamycine (Rapa). Preliminary one and three year results
demonstrated more frequent study withdrawal in the Rapa group, due to toxicity [59].
More than 60 % of those patients were rejection free at 1 year. Adequate kidney and pancreas
functions were also achieved in both groups while the serum creatinine level was significantly
lower in the Rapa group from month 2, the price to pay being hyperlipidemia, delayed wound
healing, lymphocoele or hernia.
Corticosteroid withdrawal was possible in both studies in 70 % and 50 % of recipients
respectively. Therefore, it can be concluded that steroid withdrawal is feasible in SPK trans‐
plantation but not in all patients; further studies must be designed to address that issue
completely.
4. Conclusion
The current gold standard IS therapy for all three categories of pancreas transplantation
includes induction with polyclonal antibodies and for the maintenance therapy, association of
Tac with either MMF or Rapa, the last drug being less popular at least during the first
postoperative period due to its possible side-effects (Fig 19).
Based on that potent IS therapy, functional results and patient survival rates of PT are coming
closer to those currently achieved in kidney transplantation (Fig 20).
SPK transplantation remains the best therapeutic approach for type 1 diabetic recipients with
(pre) end-stage renal failure (creatinine clearance < 50ml/min), up to 55 years of age, without
any cardiovascular risk. They have three options: either waiting for the 2 grafts coming from
the same -cadaver or live- donor, or one graft –usually the kidney – coming from a live donor
who is in stand-by while waiting for the pancreas from a cadaver donor.
PAK can be offered to diabetic recipients who had the opportunity of having a live donor for
kidney transplantation.
For other type 1 diabetic recipients, with (pre) end-stage renal failure, more than 55 years of
age, with cardiovascular risk factors, they have 2 options: either receiving a kidney transplant
alone (and eventually waiting for islet cells) or waiting for a simultaneous islet and kidney
transplantation from the same cadaveric donor.
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PTA should be considered for selected type 1 diabetic candidate without nephropathy, with
hypoglycemia unawareness syndrom, with proliferative retinopathy. These candidates could
be also candidates for islet transplantation, knowing the fact that they will be submitted to the
same IS therapy and its long term deleterious side-effects in both options, they might also know
that, with islet insulin independence is not always achieved.
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Figure 20. International Pancreas Transplant Registry* Panel (a): Patient survival in US primary pancreas transplants
between 1/1/2007 and 12/31/2011. Panel (b): Pancreas graft function in all 3 categories (SPK, PAK, PTA). Panel (c):
One year pancreas and kidney graft function in US primary pancreas transplants, between 10/1/1988 and
12/31/2011.
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